<DOC>
	<DOCNO>NCT02160353</DOCNO>
	<brief_summary>The role study focus potential role abiraterone acetate treatment-naive patient newly diagnose high-risk localised prostate cancer require combine hormonal therapy radiotherapy .</brief_summary>
	<brief_title>Neo-adjuvant Abiraterone Prostate Study</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Provision write informed consent prior study related procedure Males age 18 year old ECOG performance status less equal 1 Life expectancy 10 year ( use MSKCC nomogram ) Pathological proven prostate carcinoma intermediate high risk recurrence define RTOG Clinically negative lymph node establish image ( pelvic CT / MRI ) , nodal sampling , dissection within 60 day prior registration , except patient lymph node equivocal questionable image eligible without biopsy node less equal 1.5cm ; node large ion image require negative biopsy eligibility No evidence bone metastases bone scan within 60 day prior registration . Equivocal bone scan finding allow plain film xrays negative metastasis . Clinical laboratory value screen : Haemoglobin great equal 10.0g/dl Absolute neutrophil count ( ANC ) ≥ 1.8 × 10 power 9/L Platelets ≥ 100 × 10 power 9/L Systolic blood pressure &lt; 160 mmHg diastolic blood pressure &lt; 95 mmHg [ Note : medically control hypertension permit ] Prostate gland size measurable transrectal ultrasound ( TRUS ) least great equal 30 cm cub baseline Patient willing use barriermethod contraception along another effective contraceptive method engage sexual activity pregnant woman woman childbearing potential ( 1 week complete treatment ) Prior treatment prostate carcinoma , include prostatectomy ; high intensity focus ultrasound cryotherapy ; hormonal manipulation ( modality ) include LHRH agonist , antiandrogen , bilateral orchidectomy ; prior concomitant chemotherapy prostate cancer ; prior radiotherapy include brachytherapy region study cancer ; radical local treatment [ Exception : Transuretheral Resection Prostate ( TRUP ) / TRUS allow ] Use urethral catheter History cardiovascular disease ; Uncontrolled hypertension [ hypertension control antihypertensive therapy permit ] , clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association Class III IV heart failure , Class II IV heart failure cardiac ejection fraction measurement &lt; 50 % Active symptomatic viral hepatitis chronic liver disease Major thoracic abdominal surgery significant traumatic injury within 4 week prior registration , plan surgery study participation / within 4 week end treatment [ Note : patient plan surgical procedure conduct local anaesthesia exclude study ] Gastrointestinal disorder interfere study drug absorption Active uncontrolled disease may require oral corticosteroid therapy Positive serology hepatitis B surface antigen hepatitis C antibody Known allergy , hypersensitivity intolerance abiraterone acetate , prednisolone , GnRH agonists excipients Contraindications use prednisolone GnRH agonists per local prescribe information Evidence significant clinical disorder laboratory find make undesirable patient participate study Any condition , opinion investigator , would compromise wellbeing patient could prevent , limit , confound protocolspecified assessment The patient othe coexist malignancy within past 5 year , resect nonmelanoma skin cancer Treatment nonapproved investigational drug within 30 day first plan dose study drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>